Effects of an SGLT2 inhibitor on the salt sensitivity of blood pressure and sympathetic nerve activity in a nondiabetic rat model of chronic kidney disease,Hypertension Research

当前位置： X-MOL 学术 › Hypertens. Res. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Effects of an SGLT2 inhibitor on the salt sensitivity of blood pressure and sympathetic nerve activity in a nondiabetic rat model of chronic kidney disease
Hypertension Research ( IF 4.3 ) Pub Date : 2020-02-14 , DOI: 10.1038/s41440-020-0410-8
Ningning Wan ₁ , Yoshihide Fujisawa ₂ , Hideki Kobara ₃ , Tsutomu Masaki ₃ , Daisuke Nakano ₁ , Asadur Rahman ₁ , Akira Nishiyama ₁

Affiliation

The glucose-lowering effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors is reduced in patients with diabetes who have chronic kidney disease (CKD). In the present study, we examined the effect of an SGLT2 inhibitor on the salt sensitivity of blood pressure (BP), circadian rhythm of BP, and sympathetic nerve activity (SNA) in nondiabetic CKD rats. Uninephrectomized Wistar rats were treated with adenine (200 mg/kg/day) for 14 days. After stabilization with a normal-salt diet (NSD, 0.3% NaCl), a high-salt diet (HSD, 8% NaCl) was administered. Mean arterial pressure (MAP) was continuously monitored using a telemetry system. We also analyzed the low frequency (LF) of systolic arterial pressure (SAP), which reflects SNA. In adenine-induced CKD rats, HSD consumption for 5 days significantly increased the mean MAP from 106 ± 2 to 148 ± 3 mmHg. However, MAP was decreased to 96 ± 3 mmHg within 24 h after switching back to a NSD ( n = 7). Treatment with an SGLT2 inhibitor, luseogliflozin (10 mg/kg/day, p.o., n = 7), significantly attenuated the HSD-induced elevation of MAP, which was associated with a reduction in LF of SAP. These data suggest that treatment with an SGLT2 inhibitor attenuates the salt sensitivity of BP, which is associated with SNA inhibition in nondiabetic CKD rats.

中文翻译：

SGLT2抑制剂对慢性肾病非糖尿病大鼠模型血压盐敏感性和交感神经活动的影响

钠-葡萄糖协同转运蛋白 2 (SGLT2) 抑制剂的降糖作用在患有慢性肾病 (CKD) 的糖尿病患者中降低。在本研究中，我们检查了 SGLT2 抑制剂对非糖尿病 CKD 大鼠血压 (BP) 盐敏感性、BP 昼夜节律和交感神经活动 (SNA) 的影响。单肾切除的 Wistar 大鼠用腺嘌呤 (200 毫克/公斤/天) 治疗 14 天。在用正常盐饮食（NSD，0.3% NaCl）稳定后，给予高盐饮食（HSD，8% NaCl）。使用遥测系统连续监测平均动脉压 (MAP)。我们还分析了反映 SNA 的收缩动脉压 (SAP) 的低频 (LF)。在腺嘌呤诱导的 CKD 大鼠中，5 天的 HSD 消耗显着增加了平均 MAP 从 106 ± 2 到 148 ± 3 mmHg。然而，在切换回 NSD 后 24 小时内 MAP 降至 96 ± 3 mmHg（n = 7）。用 SGLT2 抑制剂 luseogliflozin（10 毫克/公斤/天，口服，n = 7）治疗显着减弱了 HSD 诱导的 MAP 升高，这与 SAP LF 的降低有关。这些数据表明，SGLT2 抑制剂治疗减弱了 BP 的盐敏感性，这与非糖尿病 CKD 大鼠的 SNA 抑制有关。

更新日期：2020-02-14

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11